Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.

Abstract

Canakinumab caused fast and sustained remissions in most clinical and biochemical manifestations in all enrolled patients, with a limited efficacy in the structural lesions. Dose adjustments seem to be necessary for children and/or for patients with the most severe CAPS phenotypes. Treatment was well tolerated with a low incidence of adverse effects.